Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
Frequently asked questions
What sector does Kamada (KMDA) operate in?
Kamada belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Kamada (KMDA) current stock price?
As of the latest data, Kamada stock price is $7.92, with a previous close of $7.99. Kamada lost -$0.07 in the last trading session, representing a -0.88% loss.
What is Kamada (KMDA) current market capitalization?
Kamada market cap is approximately 456.94 million.
What is Kamada (KMDA) Earnings Per Share (EPS)?
The trailing EPS is $0.39, and the forward EPS is $0.60.
What is Kamada (KMDA) Price-to-Earnings (P/E) ratio?
Kamada current P/E ratio is 20.31, with a forward P/E of 13.27.
What is Kamada (KMDA) EBITDA?
Kamada EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 13.40 million.
Does Kamada (KMDA) pay dividends?
Yes. Kamada pays annual dividends with an annualized yield of 2.15% and an estimated annual payout of $0.17 per share.
How did Kamada (KMDA) perform in its most recent earnings report?
In the last report (June 30, 2026), Kamada posted an EPS surprise of 33.33% and a revenue surprise of -63.22%.
What is Kamada (KMDA) beta (volatility) score?
Kamada has a beta of 0.127, indicating lower volatility than the overall market.
